Published by Global Banking & Finance Review®
Posted on May 2, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GoogleThe FDA has accepted Novo Nordisk's application for oral Wegovy, a potential first oral GLP-1 for weight loss, with a decision expected by Q4.
(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its weight-loss drug Wegovy and will take a decision by the fourth quarter, the Danish drugmaker said on Friday.
The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.
Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the same active ingredient semaglutide, is already approved for blood sugar control in adults with diabetes.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)
The FDA's acceptance of Novo Nordisk's application for an oral version of the weight-loss drug Wegovy.
Wegovy is a weight-loss drug developed by Novo Nordisk, containing the active ingredient semaglutide.
GLP-1 is a class of medications used for chronic weight management and diabetes control.
Explore more articles in the Headlines category
